Adherence to clinical guidance in the prescribing of oral antithrombotic medication in patients with atrial fibrillation
- PMID: 16872029
- DOI: 10.1007/BF03167949
Adherence to clinical guidance in the prescribing of oral antithrombotic medication in patients with atrial fibrillation
Abstract
Background: Atrial fibrillation is the commonest cardiac rhythm disturbance and is an independent risk factor for stroke; however, use of oral antithrombotic therapy is reported to be suboptimal in clinical practice.
Aim: The aim of the study was to evaluate the prescribing rates of oral antithrombotic therapy in patients with atrial fibrillation to determine if prescribing patterns reflected published clinical guidance.
Method: Patients with atrial fibrillation, admitted to hospital over a 12-week period were identified and their antithrombotic therapy regimen was analysed using statistical methods.
Results: Although 87/100 patients identified were prescribed OAT, the regimen was suboptimal in 35 patients. Patients aged 75 years and older were more likelyto be receiving suboptimal oral antithrombotic treatment compared with younger patients
Conclusions: The benefits and suitability of oral antithrombotic therapy for patients of all ages need to be more comprehensively communicated to prescribers.
Similar articles
-
Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing.Age Ageing. 2002 Sep;31(5):391-6. doi: 10.1093/ageing/31.5.391. Age Ageing. 2002. PMID: 12242203
-
Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):502-508. doi: 10.1177/1074248418778804. Epub 2018 May 27. J Cardiovasc Pharmacol Ther. 2018. PMID: 29806486
-
'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28. Am J Med. 2014. PMID: 24486284
-
Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?Clin Res Cardiol. 2018 Jul;107(7):533-538. doi: 10.1007/s00392-018-1242-2. Epub 2018 Apr 20. Clin Res Cardiol. 2018. PMID: 29679144 Review.
-
Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician.J Thromb Thrombolysis. 2008 Dec;26(3):167-74. doi: 10.1007/s11239-008-0272-4. Epub 2008 Sep 21. J Thromb Thrombolysis. 2008. PMID: 18807225 Review.
Cited by
-
Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial.BMJ. 2011 Jun 23;342:d3653. doi: 10.1136/bmj.d3653. BMJ. 2011. PMID: 21700651 Free PMC article. Clinical Trial.
-
Stroke and Death Prediction with the Impact of Vascular Disease in Patients with Atrial Fibrillation.J Atr Fibrillation. 2012 Jun 15;5(1):586. doi: 10.4022/jafib.586. eCollection 2012 Jun-Jul. J Atr Fibrillation. 2012. PMID: 28496751 Free PMC article. Review.
-
Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient.Int J Gen Med. 2013 Mar 21;6:167-80. doi: 10.2147/IJGM.S39379. Print 2013. Int J Gen Med. 2013. PMID: 23687449 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical